BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $98

Benzinga Newsdesk www.benzinga.com Positive 80.7%

Neg 0% Neu 0% Pos 80.7%

BTIG analyst Julian Harrison maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $70 to $98.